Obesity has a pivotal and multifaceted role in pain associated with osteoarthritis (OA),
extending beyond the mechanistic influence of BMI. It exerts its effects both directly and …

Metformin is a widely accepted first-line hypoglycemic agent in current clinical practice, and
it has been applied to the clinic for more than 60 years. Recently, researchers have …

Objective To examine whether metformin use was associated with knee cartilage volume
loss over 4 years and risk of total knee replacement over 6 years in obese individuals with …

Objective This study aimed to evaluate the effectiveness of metformin versus placebo in
overweight patients with knee osteoarthritis (OA). In addition, to assess the effects of …

Objective Osteoarthritis causes significant pain and disability with no approved disease-
modifying drugs. We systematically reviewed the evidence from both pre-clinical and human …

Metformin has been shown to modulate meta-inflammation, an important pathogenesis in
knee osteoarthritis (OA). The study aimed to test the association between regular metformin …

Objectives: We aimed to examine whether metformin (MET) use is associated with a
reduced risk of total knee arthroplasty (TKA) and low severity of knee pain in patients with …

Thiazolidinediones (TZDs) are a group of diabetes medications currently being investigated
for anti-arthritis effectiveness, one of which is pioglitazone. The purpose of this scoping …

Osteoarthritis is a chronic and irreversible disease of the locomotor system which is closely
associated with advancing age. Pain and limited mobility frequently affect the quality of life in …

Introduction Over half of the populations with knee osteoarthritis (OA) have obesity. These
individuals have many other shared metabolic risk factors. Metformin is a safe, inexpensive …